NSF board member resigns, saying Trump’s policies have harmed the agency
By Jeffrey Mervis,
Science
| 05. 13. 2025
“Alondra Nelson” by Sage Ross on Wikimedia Commons
licensed under CC by SA 2.0
In an unprecedented move, a member of the governing body for the National Science Foundation (NSF) resigned today, saying the presidentially appointed advisory board has become a “ceremonial assemblage … without consequence” during the first months of President Donald Trump’s administration.
Sociologist Alondra Nelson was appointed to the National Science Board (NSB) in the final months of former President Joe Biden’s administration, where she had served as acting director of the White House Office of Science and Technology Policy before returning to the Institute for Advanced Study in 2023. Her departure, which she announced this morning in an essay in Time, is believed to be the first time in the agency’s 75-year history that a member of the 24-person board resigned over a policy disagreement with an administration.
“The board should have been far more communicative—with both congressional leaders and the American public—about the changes occurring at NSF,” Nelson tells Science. “Even if these actions were taken without the board’s input or consent, I...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...